Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)

Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)

The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: TATJANA MATEOVIC, DORIS TIBAUT, SHIZUKO MURAOKA, GRETA COF, ANTON STALC, JANEZ KERK, MARIJA BOGATAJ, FUMIO YONEDA, ROK DREU, ANTON LAVRIC, UROS URLEB, ALES MRHAR, MANICA CERNE
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator TATJANA MATEOVIC
DORIS TIBAUT
SHIZUKO MURAOKA
GRETA COF
ANTON STALC
JANEZ KERK
MARIJA BOGATAJ
FUMIO YONEDA
ROK DREU
ANTON LAVRIC
UROS URLEB
ALES MRHAR
MANICA CERNE
description The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2005226927A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2005226927A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2005226927A13</originalsourceid><addsrcrecordid>eNqNjLsKwjAYRrs4iPoOAZd2CNTUC47FK1icdC4_adoEciP5C9ant4IPIHxwlnO-afK-QMTggogqIlgkXkIwwEWPioMmjYvQCdK6YAh3xgcVle3InabsOy9RglZGNU6gdK8ho2OLg85oRUGDHTQ90k73CEZxAlw1JK1udM2KbJ5MWtBRLH6cJcvz6XG4UuFdLaIfj6zAunyyPN8wtt2zXbkq_rM-qQNFoQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)</title><source>esp@cenet</source><creator>TATJANA MATEOVIC ; DORIS TIBAUT ; SHIZUKO MURAOKA ; GRETA COF ; ANTON STALC ; JANEZ KERK ; MARIJA BOGATAJ ; FUMIO YONEDA ; ROK DREU ; ANTON LAVRIC ; UROS URLEB ; ALES MRHAR ; MANICA CERNE</creator><creatorcontrib>TATJANA MATEOVIC ; DORIS TIBAUT ; SHIZUKO MURAOKA ; GRETA COF ; ANTON STALC ; JANEZ KERK ; MARIJA BOGATAJ ; FUMIO YONEDA ; ROK DREU ; ANTON LAVRIC ; UROS URLEB ; ALES MRHAR ; MANICA CERNE</creatorcontrib><description>The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2005</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20051006&amp;DB=EPODOC&amp;CC=AU&amp;NR=2005226927A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20051006&amp;DB=EPODOC&amp;CC=AU&amp;NR=2005226927A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TATJANA MATEOVIC</creatorcontrib><creatorcontrib>DORIS TIBAUT</creatorcontrib><creatorcontrib>SHIZUKO MURAOKA</creatorcontrib><creatorcontrib>GRETA COF</creatorcontrib><creatorcontrib>ANTON STALC</creatorcontrib><creatorcontrib>JANEZ KERK</creatorcontrib><creatorcontrib>MARIJA BOGATAJ</creatorcontrib><creatorcontrib>FUMIO YONEDA</creatorcontrib><creatorcontrib>ROK DREU</creatorcontrib><creatorcontrib>ANTON LAVRIC</creatorcontrib><creatorcontrib>UROS URLEB</creatorcontrib><creatorcontrib>ALES MRHAR</creatorcontrib><creatorcontrib>MANICA CERNE</creatorcontrib><title>Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)</title><description>The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2005</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjLsKwjAYRrs4iPoOAZd2CNTUC47FK1icdC4_adoEciP5C9ant4IPIHxwlnO-afK-QMTggogqIlgkXkIwwEWPioMmjYvQCdK6YAh3xgcVle3InabsOy9RglZGNU6gdK8ho2OLg85oRUGDHTQ90k73CEZxAlw1JK1udM2KbJ5MWtBRLH6cJcvz6XG4UuFdLaIfj6zAunyyPN8wtt2zXbkq_rM-qQNFoQ</recordid><startdate>20051006</startdate><enddate>20051006</enddate><creator>TATJANA MATEOVIC</creator><creator>DORIS TIBAUT</creator><creator>SHIZUKO MURAOKA</creator><creator>GRETA COF</creator><creator>ANTON STALC</creator><creator>JANEZ KERK</creator><creator>MARIJA BOGATAJ</creator><creator>FUMIO YONEDA</creator><creator>ROK DREU</creator><creator>ANTON LAVRIC</creator><creator>UROS URLEB</creator><creator>ALES MRHAR</creator><creator>MANICA CERNE</creator><scope>EVB</scope></search><sort><creationdate>20051006</creationdate><title>Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)</title><author>TATJANA MATEOVIC ; DORIS TIBAUT ; SHIZUKO MURAOKA ; GRETA COF ; ANTON STALC ; JANEZ KERK ; MARIJA BOGATAJ ; FUMIO YONEDA ; ROK DREU ; ANTON LAVRIC ; UROS URLEB ; ALES MRHAR ; MANICA CERNE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2005226927A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2005</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>TATJANA MATEOVIC</creatorcontrib><creatorcontrib>DORIS TIBAUT</creatorcontrib><creatorcontrib>SHIZUKO MURAOKA</creatorcontrib><creatorcontrib>GRETA COF</creatorcontrib><creatorcontrib>ANTON STALC</creatorcontrib><creatorcontrib>JANEZ KERK</creatorcontrib><creatorcontrib>MARIJA BOGATAJ</creatorcontrib><creatorcontrib>FUMIO YONEDA</creatorcontrib><creatorcontrib>ROK DREU</creatorcontrib><creatorcontrib>ANTON LAVRIC</creatorcontrib><creatorcontrib>UROS URLEB</creatorcontrib><creatorcontrib>ALES MRHAR</creatorcontrib><creatorcontrib>MANICA CERNE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TATJANA MATEOVIC</au><au>DORIS TIBAUT</au><au>SHIZUKO MURAOKA</au><au>GRETA COF</au><au>ANTON STALC</au><au>JANEZ KERK</au><au>MARIJA BOGATAJ</au><au>FUMIO YONEDA</au><au>ROK DREU</au><au>ANTON LAVRIC</au><au>UROS URLEB</au><au>ALES MRHAR</au><au>MANICA CERNE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)</title><date>2005-10-06</date><risdate>2005</risdate><abstract>The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_AU2005226927A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T14%3A09%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TATJANA%20MATEOVIC&rft.date=2005-10-06&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2005226927A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true